J Mendelson

Summary

Affiliation: California Pacific Medical Center Research Institute
Country: USA

Publications

  1. ncbi A phase 1 trial of pharmacologic interactions between transdermal selegiline and a 4-hour cocaine infusion
    Debra S Harris
    Department of Psychiatry, University of Cincinnati, OH, USA
    BMC Clin Pharmacol 9:13. 2009
  2. ncbi Human pharmacology of the methamphetamine stereoisomers
    John Mendelson
    Addiction Pharmacology Research Laboratory, California Pacific Medical Center Research Institute, St Luke s Hospital, San Francisco, CA 94110, USA
    Clin Pharmacol Ther 80:403-20. 2006
  3. ncbi The effects of inhaled L-methamphetamine on athletic performance while riding a stationary bike: a randomised placebo-controlled trial
    F Dufka
    Addiction Pharmacology Lab, California Pacific Medical Center Research Institute, 3555 Cesar Chavez, San Francisco, CA 94110, USA
    Br J Sports Med 43:832-5. 2009
  4. ncbi Addiction to prescription opioids: characteristics of the emerging epidemic and treatment with buprenorphine
    John Mendelson
    California Pacific Medical Center Research Institute, St Luke s Hospital, and Department of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, CA 94110, USA
    Exp Clin Psychopharmacol 16:435-41. 2008
  5. ncbi The clinical pharmacology of intranasal l-methamphetamine
    John E Mendelson
    Addiction Pharmacology Research Laboratory, The California Pacific Medical Center Research Institute, St Luke s Hospital, 7th Floor, 3555 Cesar Chavez Street, San Francisco, CA 94110, USA
    BMC Clin Pharmacol 8:4. 2008
  6. ncbi A method to quantify illicit intake of drugs from urine: methamphetamine
    Linghui Li
    Addiction Pharmacology Research Laboratory, California Pacific Medical Center Research Institute, San Francisco, California, USA
    J Pharmacol Exp Ther 338:31-6. 2011
  7. ncbi Repeated psychological stress testing in stimulant-dependent patients
    Debra S Harris
    Drug Dependence Research Center, Langley Porter Psychiatric Institute, Department of Psychiatry, University of California, San Francisco, CA, USA
    Prog Neuropsychopharmacol Biol Psychiatry 29:669-77. 2005
  8. ncbi Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality
    Debra S Harris
    Drug Dependence Research Center, Langley Porter Psychiatric Institute, University of California, San Francisco, San Francisco, California 94143-0984, USA
    Clin Pharmacokinet 43:329-40. 2004
  9. ncbi The bioavailability of intranasal and smoked methamphetamine
    Debra S Harris
    Drug Dependence Research Center, Langley Porter Psychiatric Institute, University of California, San Francisco, CA 94143-0984, USA
    Clin Pharmacol Ther 74:475-86. 2003
  10. ncbi Altering cortisol level does not change the pleasurable effects of methamphetamine in humans
    Debra S Harris
    Drug Dependence Research Center, Langley Porter Psychiatric Institute, Department of Psychiatry, University of California, San Francisco, CA 94143 0984, USA
    Neuropsychopharmacology 28:1677-84. 2003

Research Grants

  1. MDMA Dependence and Discontinuation Syndrome
    John Mendelson; Fiscal Year: 2007
  2. CLINICAL PHARMACOLOGY OF METHAMPHETAMINE STEREOISOMERS
    John Mendelson; Fiscal Year: 2003
  3. Clinical Pharmacology of 3,4-Methylenedioxy Amphetamines
    John E Mendelson; Fiscal Year: 2010

Collaborators

Detail Information

Publications11

  1. ncbi A phase 1 trial of pharmacologic interactions between transdermal selegiline and a 4-hour cocaine infusion
    Debra S Harris
    Department of Psychiatry, University of Cincinnati, OH, USA
    BMC Clin Pharmacol 9:13. 2009
    ..5 mg/kg of cocaine administered over 4 hours...
  2. ncbi Human pharmacology of the methamphetamine stereoisomers
    John Mendelson
    Addiction Pharmacology Research Laboratory, California Pacific Medical Center Research Institute, St Luke s Hospital, San Francisco, CA 94110, USA
    Clin Pharmacol Ther 80:403-20. 2006
    ..To help predict the consequences of precursor regulation, we compared the pharmacokinetics and pharmacodynamics of the methamphetamine (INN, metamfetamine) stereoisomers...
  3. ncbi The effects of inhaled L-methamphetamine on athletic performance while riding a stationary bike: a randomised placebo-controlled trial
    F Dufka
    Addiction Pharmacology Lab, California Pacific Medical Center Research Institute, 3555 Cesar Chavez, San Francisco, CA 94110, USA
    Br J Sports Med 43:832-5. 2009
    ..This study tested the effects of inhaled L-methamphetamine delivered from a widely available non-prescription product on athletic performance...
  4. ncbi Addiction to prescription opioids: characteristics of the emerging epidemic and treatment with buprenorphine
    John Mendelson
    California Pacific Medical Center Research Institute, St Luke s Hospital, and Department of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, CA 94110, USA
    Exp Clin Psychopharmacol 16:435-41. 2008
    ....
  5. ncbi The clinical pharmacology of intranasal l-methamphetamine
    John E Mendelson
    Addiction Pharmacology Research Laboratory, The California Pacific Medical Center Research Institute, St Luke s Hospital, 7th Floor, 3555 Cesar Chavez Street, San Francisco, CA 94110, USA
    BMC Clin Pharmacol 8:4. 2008
    ..We studied the pharmacology of l-methamphetamine, the less abused isomer, when used as a nasal decongestant...
  6. ncbi A method to quantify illicit intake of drugs from urine: methamphetamine
    Linghui Li
    Addiction Pharmacology Research Laboratory, California Pacific Medical Center Research Institute, San Francisco, California, USA
    J Pharmacol Exp Ther 338:31-6. 2011
    ..The method reliably detects small, clinically relevant changes in illicit MA intake from random urine specimens, is amenable to deployment in clinical trials, and can be used to quantify patterns of MA abuse...
  7. ncbi Repeated psychological stress testing in stimulant-dependent patients
    Debra S Harris
    Drug Dependence Research Center, Langley Porter Psychiatric Institute, Department of Psychiatry, University of California, San Francisco, CA, USA
    Prog Neuropsychopharmacol Biol Psychiatry 29:669-77. 2005
    ..Although less convincing because of the heterogeneity of the subjects, they also suggest that HPA axis responsivity is not clearly linked to acute stress-induced stimulant craving or affective response...
  8. ncbi Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality
    Debra S Harris
    Drug Dependence Research Center, Langley Porter Psychiatric Institute, University of California, San Francisco, San Francisco, California 94143-0984, USA
    Clin Pharmacokinet 43:329-40. 2004
    ..CONCLUSION: Less than dose-proportional increases in plasma buprenorphine concentrations may contribute to the observed plateau for most pharmacodynamic effects as the dose is increased...
  9. ncbi The bioavailability of intranasal and smoked methamphetamine
    Debra S Harris
    Drug Dependence Research Center, Langley Porter Psychiatric Institute, University of California, San Francisco, CA 94143-0984, USA
    Clin Pharmacol Ther 74:475-86. 2003
    ..Although intranasal or smoked routes may decrease the risk of transmission of blood-borne diseases, exposure to methamphetamine and the possibility of drug-related complications remain substantial...
  10. ncbi Altering cortisol level does not change the pleasurable effects of methamphetamine in humans
    Debra S Harris
    Drug Dependence Research Center, Langley Porter Psychiatric Institute, Department of Psychiatry, University of California, San Francisco, CA 94143 0984, USA
    Neuropsychopharmacology 28:1677-84. 2003
    ..Metyrapone was associated with significant premature ventricular complexes in two subjects during methamphetamine administration and may not be safe for those who use methamphetamine...
  11. ncbi Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans
    Debra S Harris
    Drug Dependence Research Center, Langley Porter Psychiatric Institute, University of California, San Francisco, 401 Parnassus Avenue, San Francisco, CA 94143 0984, USA
    Psychopharmacology (Berl) 162:396-405. 2002
    ..3,4-Methylenedioxymethamphetamine (MDMA) is a widely used phenethylamine. Reports have described the effects of MDMA in a controlled laboratory setting, but the full range of effects of MDMA in humans is still not completely characterized...

Research Grants14

  1. MDMA Dependence and Discontinuation Syndrome
    John Mendelson; Fiscal Year: 2007
    ..Addiction to MDMA appears to be a serious risk of use; our studies will carefttlly define important clinical features of this emerging disorder. ..
  2. CLINICAL PHARMACOLOGY OF METHAMPHETAMINE STEREOISOMERS
    John Mendelson; Fiscal Year: 2003
    ..Primary outcome measures include drug and metabolite measurements in plasma and urine and subjective and cardiovascular measures, including 2D echocardiography. ..
  3. Clinical Pharmacology of 3,4-Methylenedioxy Amphetamines
    John E Mendelson; Fiscal Year: 2010
    ..This experiment will investigate the role of alpha-1 adrenergic receptors in the action of MDMA and will provide preliminary data on the possible use of prazosin in the treatment of acute MDMA toxicity. ..